CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
诱导西妥昔单抗在 p16 阳性口咽癌减强度治疗 II 期试验中对肿瘤免疫微环境的影响
英文原题：Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer.
查看英文原题
Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
在 1 周内，西妥昔单抗诱导了可测量的促细胞毒性 T 细胞信号传导和免疫内容物的变化。
研究思路结论见上方概要
我们旨在在一个p16阳性口咽癌队列的II期临床降阶梯试验中，描述诱导西妥昔单抗治疗后CD8+TIL（肿瘤浸润淋巴细胞）和肿瘤转录组的早期变化。
在纳入西妥昔单抗联合放疗II期试验的八名患者中，于单次西妥昔单抗负荷剂量前及1周后获取肿瘤活检。评估了CD8+TIL（肿瘤浸润淋巴细胞）和转录组的变化。
西妥昔单抗治疗一周后，5例患者（62.5%）CD8+细胞浸润增加，中位（范围）倍数变化为+5.8（2.5-15.8）。3例（37.5%）CD8+细胞无变化（中位[范围]倍数变化为-0.85[0.8-1.1]）。在2例可评估RNA的患者中，西妥昔单抗诱导了肿瘤转录组在细胞1型干扰素信号传导和角化途径方面的快速变化。
展开英文摘要原文
We sought to characterize early changes in CD8 + tumor-infiltrating lymphocytes and tumor transcriptomes after induction cetuximab in a cohort with p16-positive oropharyngeal cancer on a phase II clinical de-escalation trial.
Tumor biopsies were obtained before and 1 week after a single cetuximab loading dose in eight patients enrolled in a phase II trial of cetuximab and radiotherapy. Changes in CD8 + tumor-infiltrating lymphocytes and transcriptomes were assessed.
One week after cetuximab, five patients (62.5%) had an increase in CD8 + cell infiltration with a median (range) fold change of +5.8 (2.5-15.8). Three (37.5%) had unchanged CD8 + cells (median [range] fold change of -0.85 [0.8-1.1]). In two patients with evaluable RNA, cetuximab induced rapid tumor transcriptome changes in cellular type 1 interferon signaling and keratinization pathways.
Within 1 week, cetuximab induced measurable changes in pro-cytotoxic T-cell signaling and immune content.
论文信息
- 作者
- Smith JD、Ludwig ML、Bhangale AD、Brummel C、Swiecicki PL、Worden FP、Chinn SB、Stucken CL
- 单位
- Department of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.United States
- 文献类型
- II 期临床试验 · 美国 NIH 资助研究 · 非美国政府资助研究
- 期刊
- Head & neck2023 May
- 原文标识
- PubMed 36932871 · DOI 10.1002/hed.27344
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →